Forro B, Kajtar B, Lacza A, Kereskai L, Vida L, Koszegi B
Front Immunol. 2025; 16:1464940.
PMID: 40079005
PMC: 11896981.
DOI: 10.3389/fimmu.2025.1464940.
Wang P, Wang Y, Zhao X, Zheng R, Zhang Y, Meng R
Signal Transduct Target Ther. 2025; 10(1):20.
PMID: 39809749
PMC: 11733243.
DOI: 10.1038/s41392-024-02096-5.
Elizaldi S, Hawes C, Verma A, Lakshmanappa Y, Dinasarapu A, Schlegel B
J Clin Invest. 2024; 134(9).
PMID: 38470479
PMC: 11060742.
DOI: 10.1172/JCI175332.
Mu S, Chen L, Dong H, Li S, Zhang Y, Yin S
J Virol. 2024; 98(2):e0200223.
PMID: 38289108
PMC: 10878267.
DOI: 10.1128/jvi.02002-23.
Tang J, Jia X, Li J, Dong J, Wang J, Li W
Cell Mol Immunol. 2023; 20(5):512-524.
PMID: 36977779
PMC: 10203318.
DOI: 10.1038/s41423-023-00997-z.
A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
Xia L, Yuan L, Hu Y, Liu J, Hu G, Qi R
Cell Mol Immunol. 2023; 20(4):351-364.
PMID: 36864189
PMC: 9979130.
DOI: 10.1038/s41423-023-00985-3.
Low-density lipoprotein balances T cell metabolism and enhances response to anti-PD-1 blockade in a HCT116 spheroid model.
Babl N, Hofbauer J, Matos C, Voll F, Menevse A, Rechenmacher M
Front Oncol. 2023; 13:1107484.
PMID: 36776340
PMC: 9911890.
DOI: 10.3389/fonc.2023.1107484.
The Regulatory-T-Cell Memory Phenotype: What We Know.
Khantakova J, Bulygin A, Sennikov S
Cells. 2022; 11(10).
PMID: 35626725
PMC: 9139615.
DOI: 10.3390/cells11101687.
Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells.
Krause N, Mengwasser J, Phithak E, Beato F, Appis M, Milford E
Front Immunol. 2022; 12:790775.
PMID: 35222353
PMC: 8867398.
DOI: 10.3389/fimmu.2021.790775.
CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties.
Vlaming M, Bilemjian V, Freile J, Lourens H, van Rooij N, Huls G
Sci Rep. 2021; 11(1):20499.
PMID: 34654826
PMC: 8520003.
DOI: 10.1038/s41598-021-00007-0.
Plasma Membrane Calcium ATPase Regulates Stoichiometry of CD4 T-Cell Compartments.
Merino-Wong M, Niemeyer B, Alansary D
Front Immunol. 2021; 12:687242.
PMID: 34093590
PMC: 8175910.
DOI: 10.3389/fimmu.2021.687242.
How to Reliably Define Human CD8 T-Cell Subsets: Markers Playing Tricks.
van Aalderen M, van Lier R, Hombrink P
Cold Spring Harb Perspect Biol. 2021; 13(11).
PMID: 33782028
PMC: 8559543.
DOI: 10.1101/cshperspect.a037747.
Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms.
MacFarlane 4th A, Yeung H, Alpaugh R, Dulaimi E, Engstrom P, Dasari A
Cancer Immunol Immunother. 2021; 70(7):1893-1906.
PMID: 33398390
PMC: 8195815.
DOI: 10.1007/s00262-020-02811-5.
Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function.
Ukidve A, Zhao Z, Fehnel A, Krishnan V, Pan D, Gao Y
Proc Natl Acad Sci U S A. 2020; 117(30):17727-17736.
PMID: 32665441
PMC: 7395435.
DOI: 10.1073/pnas.2002880117.
Transcriptome profiling of human thymic CD4+ and CD8+ T cells compared to primary peripheral T cells.
Helgeland H, Gabrielsen I, Akselsen H, Sundaram A, Flam S, Lie B
BMC Genomics. 2020; 21(1):350.
PMID: 32393182
PMC: 7216358.
DOI: 10.1186/s12864-020-6755-1.
Memory T cells: strategies for optimizing tumor immunotherapy.
Liu Q, Sun Z, Chen L
Protein Cell. 2020; 11(8):549-564.
PMID: 32221812
PMC: 7381543.
DOI: 10.1007/s13238-020-00707-9.
Memory CD4 T Cells in Immunity and Autoimmune Diseases.
Raphael I, Joern R, Forsthuber T
Cells. 2020; 9(3).
PMID: 32106536
PMC: 7140455.
DOI: 10.3390/cells9030531.
Single-Cell RNA-Sequencing Identifies Activation of TP53 and STAT1 Pathways in Human T Lymphocyte Subpopulations in Response to Ex Vivo Radiation Exposure.
Moreno-Villanueva M, Zhang Y, Feiveson A, Mistretta B, Pan Y, Chatterjee S
Int J Mol Sci. 2019; 20(9).
PMID: 31083348
PMC: 6539494.
DOI: 10.3390/ijms20092316.
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer M, Riviere I, Senechal B, Wang X, Wang Y, Purdon T
JCI Insight. 2019; 5.
PMID: 30938714
PMC: 6538317.
DOI: 10.1172/jci.insight.122627.
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S, Chakraborty P, Daenthanasanmak A, Iamsawat S, Andrejeva G, Luevano L
Clin Cancer Res. 2018; 25(3):1036-1049.
PMID: 30327305
PMC: 6361669.
DOI: 10.1158/1078-0432.CCR-18-0706.